Table 1 CSF and serum concentrations of glucagon-1 and cell viability following implantation of encapsulated genetically-engineered stem cells into three intracerebral sites in cats
Implantation Site | Subdural (n = 4) | Intracerebral (n = 5) | Intraventricular (n = 4) |
|---|---|---|---|
CSF GLP-1 concentration [pM] | 14d: 2.3/2.5/<2/2.2 | 14 d: <2/<2/<2/<2/<2 | Day zero: <2/<2/<2/<2 7d: NA**/63/6/73 14d: 47/44/8/<2 |
Serum GLP-1 concentration [pM] | NA | NA | Day zero: <2.5(all) 7d: <2.5(all) 14 d: <2.5(all) |
GLP-1 secretion prior to implantation (fmol/h/capsule) | 3.6 (all) | 4.6 (all) | 4.6 (all) |
GLP-1 secretion post implantation (fmol/h/capsule) | NA*/ NA* / 0.6 / 3.0 | 1.6/ 1.2 / 1.6 / 1.7/ 3.5 | 0.9/ 1.6/ 1.5 / 1.9 |
Viability of cells / capsule (SYBRGreen/ propidium iodide) | NA*/NA*/< 10%/40% | 53%/58%/20%/83%/70% | 41%/52%/51%/53% |